01. Product portfolioProTransStudy TeamCellaviva
02. About NextCellBusiness ConceptVision, mission, strategyHistory
OrganisationCompany Structure
03. InvestorsRights Issue 2024NextCell as an investmentFinancial CalendarFinancial ReportsCorporate GovernanceCertified AdviserThe ShareArchive
04. NewsPress ReleasesNextCell in the mediaEventsCompany PresentationsQ&A with CEO
05. ContactContact InformationSubscribe
English
/
Svenska

NextCell invited to speak at Advance Therapies Congress in London

May 24, 2022

The first patient was treated with ProTrans in January 2018 and there are presently 4 clinical trials and one follow-up study ongoing. The active pharmaceutical ingredient in ProTrans is mesenchymal stromal cells from umbilical cord tissue. The patent pending selection algorithm is utilized for selection of cells and donors to ensure a drug product with immunomodulary capacity.

“It is a privilege to present NextCell’s impressive clinical trial program”, say Mathias Svahn.

The Andvanced Therapies Congress will bring together 1 200 attendees from across the advanced therapy medicinal product, ATMP industry from pharma, biotech, research, regulatory bodies and start-ups. During the last 2 years the Advanced Therapies Industry has seen great leaps forward in innovation, creative solutions to challenging setbacks, new technologies, interest, and investment.

For more information about NextCell Pharma AB, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: 08-735 5595
E-mail: info@nextcellpharma.com

Websites:
www.nextcellpharma.com
www.cellaviva.se
www.cellaviva.dk
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
Instagram: https://www.instagram.com/cellaviva/

Certified Adviser
FNCA Sweden AB is assigned as Certified Adviser, 08-528 00 399, info@fnca.se.
‍

About NextCell Pharma AB
‍NextCell is a phase II cell therapy company with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to take ProTrans to market approval via a Phase III study. ProTrans is in addition to diabetes, used in two clinical trials for Covid-19, in Örebro and Montreal (Canada). The company is in the processes of establishing its own GMP facility for production of ProTrans. The GMP facility is expected to be ready for production of smaller quantities of ProTrans in 2023. NextCell furthermore owns 8,5% in FamicordTX, a CAR-T start-up in oncology and 100% of Cellaviva, Scandinavia's largest stem cell bank for family saving stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).

Download attachmentRead full press release on Cision (external link)
2022-04-28
NextCell Pharma publishes Interim Report 2 2021/2022
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period September 1, 2021 – February 28, 2022 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth M
Read moreRead more
2022-04-26
NextCell is attending a conference for worldleading celltherapies
NextCell Pharma AB ("NextCell" or the"Company") is attending the International Society for Cell and Gene Therapy 2022 in San Francisco, May 4-7. The company is represented by Mathias Svahn, CEO who is a member of the Business Development and Finance Committee will participate in workshops, round t
Read moreRead more
2022-04-07
First age group treated in paediatric diabetes study with ProTrans
NextCell Pharma AB ("NextCell") today announces that all three children in the age group 12-18 years have been treated with ProTrans. Professor Per-Ola Carlsson and the study team are now moving forward with younger patients, three children in the age group 7-11 years.
Read moreRead more
2022-04-01
Cellaviva delivers stem cells to treat serious blood disease
NextCell Pharma AB ("NextCell" or the ”Company”) announces that the stem cell bank Cellaviva has released umbilical cord blood stem cells to Rigshospitalet, Denmark's leading hospital.
Read moreRead more
2022-02-22
The Canadian ProTrans in COVID-19 single center trial is expanded to a multicenter trial
NextCell Pharma AB (“NextCell”) today announces that the clinical trial ProTrans19+CA expanded to include an additional site: the Jewish General Hospital in Montreal, Canada.  The hospital is one of the largest in Canada and is affiliated with the trial Sponsor, the Research Institute of McGill University Health Center. Patient enrolment increased due to the omicron variant, which we envisage will be further enhanced by patient reqruitment at both sites, the Royal Victoria and Jewish General Hospital. The coronavirus pandemic has transformed over time and omicron has shown to be more
NextCell Pharma AB (“NextCell”) today announces that the clinical trial ProTrans19+CA expanded to include an additional site: the Jewish General Hospital in Montreal, Canada.  The hospital is one of the largest in Canada and is affiliated with the trial Sponsor, the Research Institute of McGill U...
Read moreRead more
2022-02-21
Pediatric diabetes study with ProTrans in progress
NextCell Pharma AB ("NextCell") has previously announced a clinical trial with ProTrans™ to treat children and adolescents with type 1 diabetes. The study recently started with screening of patients. Before treatment, patients are followed for about a month and the first adolescents will soon undergo treatment. The first part of the study is a safety part (phase Ib) where all patients are treated at Akademiska university hospital. 3 patients aged 12-18 years receive treatment first and there after 3 patients aged 7-11 years. The data will then be reviewed by the Data Safety Monitoring Board,
NextCell Pharma AB ("NextCell") has previously announced a clinical trial with ProTrans™ to treat children and adolescents with type 1 diabetes. The study recently started with screening of patients. Before treatment, patients are followed for about a month and the first adolescents will soon und...
Read moreRead more
2022-02-18
NextCell Pharma presents at Redeye Theme: Regenerative Medicine/Cell Therapy
On February 23rd at 10.40 CET Dr. Mathias Svahn, CEO of NextCell Pharma AB (“NextCell" or the"Company"), will present the latest developments in the company at Redeye. The presentation is live broadcasted and can be followed at https://www.redeye.se/events/825130/redeye-theme-regenerative-medicine-cell-therapy where the replay and the presentations will be available afterwards.
On February 23rd at 10.40 CET Dr. Mathias Svahn, CEO of NextCell Pharma AB (“NextCell" or the"Company"), will present the latest developments in the company at Redeye. The presentation is live broadcasted and can be followed at https://www.redeye.se/events/825130/redeye-theme-regenerative-medici...
Read moreRead more
2022-02-08
NextCell invests in CAR-T technology
NextCell Pharma AB ("NextCell" or the"Company") informs that FamiCordTx, a joint venture cell-gene biopharma company issues new share. The major shareholders, PBKM and NextCell will participate at 50% of their pro rata rights. For NextCell this results in an investment of approximately kEUR 160, whereas its ownership in FamiCordTx will change from 9,43% to 8,45% of the then shares. FamiCordTx S.A., raised PLN 16 million (approximatly MEUR 3,5) from a pre-IPO issue of shares •  The proceeds from the issue will be used to fund the Phase 1 clinical trials of CAR T (chimeric antigen receptor
NextCell Pharma AB ("NextCell" or the"Company") informs that FamiCordTx, a joint venture cell-gene biopharma company issues new share. The major shareholders, PBKM and NextCell will participate at 50% of their pro rata rights. For NextCell this results in an investment of approximately kEUR 160, ...
Read moreRead more
This website uses cookies in order to improve the user experience. Read more
Preferences
DenyAccept